Lupin gets 5 observations from USFDA for its Vizag Manufacturing facility
Lupin gets 5 observations from USFDA. The United States Food and Drug Administration (USFDA) inspected the Lupin’s API manufacturing facility at Vizag. The pharmaceutical company disclosed it on Saturday and revealed that the inspection executed between January 13 to January 17. It also said that the inspection closed with five 483 observations.
The Lupin’s Managing Director Nilesh Gupta said that we bound to CGMP regulations and continue to maintain high-quality standards in all our manufacturing sites. He later added that we are sure of addressing the observations to the USFDA’s satisfaction.